# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 pri...
TransCode Therapeutics shares are trading lower by 40.6% during Monday's session. The company disclosed plans for a potenti...
The Board and Management of TransCode Therapeutics (NASDAQ:RNAZ) today issued the following open letter to shareholders of the ...
HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 pri...
HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 pri...